Galectin Therapeutics Inc. Share Price
GALTGalectin Therapeutics Inc. Stock Performance
Open $2.22 | Prev. Close $2.21 | Circuit Range N/A |
Day Range $2.21 - $2.56 | Year Range $1.22 - $7.13 | Volume 23,844 |
Average Traded $2.47 |
Galectin Therapeutics Inc. Share Price Chart
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin Therapeutics Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
21-May-26 | $2.22 | $2.54 | +0.00% |
21-May-26 | $2.22 | $2.54 | +14.71% |
20-May-26 | $2.08 | $2.21 | +6.25% |
19-May-26 | $2.11 | $2.08 | -5.24% |
18-May-26 | $2.26 | $2.19 | +0.69% |
15-May-26 | $2.26 | $2.18 | -7.43% |
14-May-26 | $2.34 | $2.35 | +5.61% |